CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Attention: President and CEO...Santarus Inc • May 5th, 2011 • Pharmaceutical preparations
This letter shall be governed by, and construed and enforced in accordance with the laws of New York. Each party submits to the jurisdiction of the courts of New York.
FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • May 5th, 2011 • Santarus Inc • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENT (this “Amendment”) is made as of March 10, 2011 (the “Effective Date”), by and among VeroScience, LLC, a Delaware limited liability company (“VeroScience”), S2 Therapeutics, Inc. f/k/a Wythe Therapeutics, Inc., a Tennessee corporation (“S2”), and Santarus, Inc., a Delaware corporation (“Santarus”). Each of VeroScience, S2 and Santarus is referred to herein individually as a “party” and collectively as the “parties.”
AMENDMENT NO. 3 TO OTC LICENSE AGREEMENTOtc License Agreement • May 5th, 2011 • Santarus Inc • Pharmaceutical preparations
This Amendment No. 3 (the “Amendment”) to the OTC License Agreement dated October 17, 2006, as amended (the “License”), between Schering-Plough Healthcare Products, Inc. (“MCC”) and Santarus, Inc. (“Santarus”) is made as of the last date of signature below (the “Effective Date”).
